TY - JOUR
T1 - Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: Retrospective cohort study (GENE-RAD-RISK)
AU - Pijpe, Anouk
AU - Andrieu, Nadine
AU - Easton, Douglas F.
AU - Kesminiene, Ausrele
AU - Cardis, Elisabeth
AU - Noguès, Catherine
AU - Gauthier-Villars, Marion
AU - Lasset, Christine
AU - Fricker, Jean Pierre
AU - Peock, Susan
AU - Frost, Debra
AU - Evans, D. Gareth
AU - Eeles, Rosalind A.
AU - Clinical, Joan Paterson
AU - Manders, Peggy
AU - Van Asperen, Christi J.
AU - Ausems, Margreet G E M
AU - Meijers-Heijboer, Hanne
AU - Thierry-Chef, Isabelle
AU - Hauptmann, Michael
AU - Goldgar, David
AU - Rookus, Matti A.
AU - Van Leeuwen, Flora E.
N1 - C1287/A8874, Cancer Research UK, United KingdomC5047/A8385, Cancer Research UK, United KingdomR01 CA142657, NCI NIH HHS, United States
PY - 2012/10/13
Y1 - 2012/10/13
N2 - Objective: To estimate the risk of breast cancer associated with diagnostic radiation in carriers of BRCA1/2 mutations. Design: Retrospective cohort study (GENE-RAD-RISK). Setting: Three nationwide studies (GENEPSO, EMBRACE, HEBON) in France, United Kingdom, and the Netherlands, Participants: 1993 female carriers of BRCA1/2 mutations recruited in 2006-09. Main outcome measure: Risk of breast cancer estimated with a weighted Cox proportional hazards model with a time dependent individually estimated cumulative breast dose, based on nominal estimates of organ dose and frequency of self reported diagnostic procedures. To correct for potential survival bias, the analysis excluded carriers who were diagnosed more than five years before completion of the study questionnaire. Results: In carriers of BRCA1/2 mutations any exposure to diagnostic radiation before the age of 30 was associated with an increased risk of breast cancer (hazard ratio 1.90, 95% confidence interval 1.20 to 3.00), with a dose-response pattern. The risks by quarter of estimated cumulative dose
AB - Objective: To estimate the risk of breast cancer associated with diagnostic radiation in carriers of BRCA1/2 mutations. Design: Retrospective cohort study (GENE-RAD-RISK). Setting: Three nationwide studies (GENEPSO, EMBRACE, HEBON) in France, United Kingdom, and the Netherlands, Participants: 1993 female carriers of BRCA1/2 mutations recruited in 2006-09. Main outcome measure: Risk of breast cancer estimated with a weighted Cox proportional hazards model with a time dependent individually estimated cumulative breast dose, based on nominal estimates of organ dose and frequency of self reported diagnostic procedures. To correct for potential survival bias, the analysis excluded carriers who were diagnosed more than five years before completion of the study questionnaire. Results: In carriers of BRCA1/2 mutations any exposure to diagnostic radiation before the age of 30 was associated with an increased risk of breast cancer (hazard ratio 1.90, 95% confidence interval 1.20 to 3.00), with a dose-response pattern. The risks by quarter of estimated cumulative dose
U2 - 10.1136/bmj.e5660
DO - 10.1136/bmj.e5660
M3 - Article
C2 - 22956590
SN - 0959-535X
VL - 345
JO - Bmj
JF - Bmj
IS - 7878
M1 - e5660
ER -
